Eli Lilly and Company
Prescription Drugs · Cardiometabolic Therapeutics

Eli Lilly and Company: Funding & valuation

Eli Lilly and Company returned $9.5B to shareholders in fiscal 2025 and paid $10.8B of income tax.

Financials

Revenue of $65.2B in 2025. +44.7% on the year before. Net income $20.6B.

$65.2BRevenue2025 · +44.7%
$20.6BNet income2025 · +94.9%
$713.1BMarket cap2025
38,350Employees2018
Revenue by yearas filed, with the net income
2025$65.2Bnet income $20.6B
2024$45Bnet income $10.6B
2023$34.1Bnet income $5.2B
2022$28.5Bnet income $6.2B
2021$28.3Bnet income $5.6B
2020$24.5Bnet income $6.2B
2019$22.3Bnet income $8.3B
2018$21.5Bnet income $3.2B
Money by yearUSD, rounds and grants
2018$98k1 record
2015$1.5M1 record
Largest rounds and grants
2015
$1.5M
2018
$98k
Sources: SEC

Money

Eli Lilly and Company returned $9.5B to shareholders in fiscal 2025 and paid $10.8B of income tax.

$10.8BIncome taxes paidFY2025
$9.5BDividends and buybacksFY2025
StagePaidSignedAnnouncedSourceFiledAnnouncedPress
Money in
Grant
Aug 2018 · Grant
$98kPaid
Grant
May 2015 · Grant
$1.5MPaid
Loan or credit · Societe Generale, London Branch
Jun 2002 – Dec 2018 · Charge: Charge over equipment
not statedPaid
1 more record: amounts, dates and sources of every round, loan and commitmentProUnlockor this company alone for 30 days · 50 credits
From its filingssec.gov ↗
FY2023FY2024FY2025
Income taxes paid$5.6B$6.6B$10.8B
Dividends paid$4.1B$4.7B$5.4B
Shares bought back$750M$2.5B$4.1B
Stock-based compensation$629M$646M$626M
Acquisitions, net of cash–––
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".